Personal information

Countries

United States

Biography

Sr. Research Scientist at the Ben Towne Center at Seattle Children's Hospital, and Co-founder of Cyclera Therapeutics. Currently investigating novel extracellular targeted protein degradation technologies.

Formerly Director of Protein Discovery at Blaze Bioscience, Inc., before which I was Staff Scientist at the Fred Hutchinson Cancer Research Center. Previous graduate work at Massachusetts Institute of Technology, investigating mouse models of Huntington's disease and developing in vivo assays for disease progression.

Activities

Collapse all

Employment (4)

Fred Hutchinson Cancer Research Center: Seattle, WA, US

Employment
Source: check_circle
Fred Hutchinson Cancer Center

Seattle Children's Hospital: Seattle, US

2024-08 to present | Sr. Research Scientist (Ben Towne Center)
Employment
Source: Self-asserted source
Zachary R. Crook

Cyclera Therapeutics, Inc: Seattle, WA, US

2023-12 to 2024-08 | VP of Research
Employment
Source: Self-asserted source
Zachary R. Crook

Blaze Bioscience (United States): Seattle, Washington, US

2021-03-22 to 2023-04-01 | Dir. of Protein Discovery
Employment
Source: Self-asserted source
Zachary R. Crook

Education and qualifications (2)

Massachusetts Institute of Technology: Cambridge, MA, US

2007-09 to 2013-09 | Ph.D. (Biology)
Education
Source: Self-asserted source
Zachary R. Crook

University of Colorado: Boulder, Colorado, US

2003-09 to 2007-06 | BA (MCDB)
Education
Source: Self-asserted source
Zachary R. Crook

Works (13)

CYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect

Nature Communications
2024-10-09 | Journal article
DOI: 10.1038/s41467-024-52975-2
Contributors: Zachary R. Crook; Gregory P. Sevilla; Pamela Young; Emily J. Girard; Tinh-Doan Phi; Monique L. Howard; Jason Price; James M. Olson; Natalie W. Nairn
Source: check_circle
Crossref

CYpHER: Catalytic extracellular targeted protein degradation with high potency and durable effect

2024-02-23 | Preprint
DOI: 10.1101/2024.02.21.581471
Contributors: Zachary R. Crook; Gregory P. Sevilla; Pamela Young; Emily J. Girard; Tinh-Doan Phi; Monique Howard; Jason Price; James M. Olson; Natalie W. Nairn
Source: check_circle
Crossref

Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager

Science Translational Medicine
2022-05-18 | Journal article
DOI: 10.1126/scitranslmed.abn0402
Contributors: Zachary R. Crook; Emily J. Girard; Gregory P. Sevilla; Mi-Youn Brusniak; Peter B. Rupert; Della J. Friend; Mesfin M. Gewe; Midori Clarke; Ida Lin; Raymond Ruff et al.
Source: check_circle
Crossref

Mammalian Surface Display Screening of Diverse Cystine-Dense Peptide Libraries for Difficult-to-Drug Targets

Methods in Molecular Biology
2020 | Book chapter
DOI: 10.1007/978-1-4939-9853-1_21
Part of ISBN: 9781493998524
Part of ISBN: 9781493998531
Part of ISSN: 1064-3745
Part of ISSN: 1940-6029
Source: Self-asserted source
Zachary R. Crook

A TfR-Binding Cystine-Dense Peptide Promotes Blood–Brain Barrier Penetration of Bioactive Molecules

Journal of Molecular Biology
2020-06 | Journal article
DOI: 10.1016/j.jmb.2020.04.002
Part of ISSN: 0022-2836
Source: Self-asserted source
Zachary R. Crook

Miniproteins as a Powerful Modality in Drug Development

Trends in Biochemical Sciences
2020-04 | Journal article
DOI: 10.1016/j.tibs.2019.12.008
Part of ISSN: 0968-0004
Source: Self-asserted source
Zachary R. Crook

Publisher Correction: Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets

Nature Communications
2018-03-09 | Journal article
DOI: 10.1038/s41467-018-03350-5
Contributors: Zachary R. Crook; Gregory P. Sevilla; Della Friend; Mi-Youn Brusniak; Ashok D. Bandaranayake; Midori Clarke; Mesfin Gewe; Andrew J. Mhyre; David Baker; Roland K. Strong et al.
Source: check_circle
Crossref

Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets

Nature Communications
2017-12 | Journal article
DOI: 10.1038/s41467-017-02098-8
Part of ISSN: 2041-1723
Source: Self-asserted source
Zachary R. Crook
grade
Preferred source (of 2)‎

In Vivo Identification of Therapeutic Constructs from Pooled Candidates in HD Model Mice

Journal of Huntington's Disease
2013 | Journal article
DOI: 10.3233/JHD-130073
Source: Self-asserted source
Zachary R. Crook

Surveying the Landscape of Huntington's Disease Mechanisms, Measurements, and Medicines

Journal of Huntington's Disease
2013 | Journal article
DOI: 10.3233/JHD-130072
Source: Self-asserted source
Zachary R. Crook

Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice

Proceedings of the National Academy of Sciences
2012-05-08 | Journal article
DOI:

10.1073/pnas.1204542109

Part of ISSN:

0027-8424
Contributors: Z. R. Crook; D. E. Housman
Source: Self-asserted source
Zachary R. Crook via Crossref Metadata Search

Huntington's Disease: Can Mice Lead the Way to Treatment?

Neuron
2011-02 | Journal article
DOI:

10.1016/j.neuron.2010.12.035

Part of ISSN:

0896-6273
Contributors: Zachary R. Crook; David Housman
Source: Self-asserted source
Zachary R. Crook via Crossref Metadata Search

Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions: Implications for oxygen sensing and hypoxic signaling in eukaryotes

Cell Metabolism
2006-04 | Journal article
DOI:

10.1016/j.cmet.2006.02.011

Part of ISSN:

1550-4131
Contributors: Pablo R. Castello; Pamela S. David; Travis McClure; Zachary Crook; Robert O. Poyton
Source: Self-asserted source
Zachary R. Crook via Crossref Metadata Search
How many people are using ORCID?